Background
==========

Colorectal cancer (CRC) is one of the most common forms of human cancer worldwide, with approximately 1 million new cases detected every year \[[@B1]\]. Early detection, adequate surgical excision and optimal adjuvant treatment are of crucial importance if a favorable outcome is to be achieved. Currently, tumor stage at diagnosis is the most important prognostic factor in CRC, and although many efforts have been made to find molecular markers to identify high-risk disease and to select patients for adjuvant treatment, none has proven sufficiently good for use in clinical routine.

Several sex-related differences in the incidence \[[@B2]\], survival chemotherapeutic response \[[@B4]\] and certain molecular characteristics \[[@B5],[@B6]\] of CRC have been reported. Furthermore, large-scale population-based studies such as the Women\'s Health Initiative have shown a significant reduction in both the risk and rate of developing CRC in post-menopausal women treated with combined hormone replacement therapy (HRT) \[[@B7]\], and both pregnancy and the oral contraceptive pill are associated with a reduced CRC risk \[[@B8],[@B9]\]. Taken together, these data suggest that estrogens and/or progestins have a protective effect against colorectal carcinogenesis, although the molecular mechanisms behind these observations are not yet fully understood. The effects of estrogens are mediated by estrogen receptors (ERs), of which two (ERα and ERβ) exist, with ERβ being the predominant ER expressed in CRC \[[@B10]-[@B12]\].

Cyclin D1 is an important cell-cycle regulating protein that, together with its binding partners cyclin-dependent kinase (CDK)4 and CDK6, forms active complexes that promote G1- to S-phase progression by phosphorylating and inactivating the retinoblastoma protein \[[@B13]\]. More recent studies have also revealed important CDK-independent functions of cyclin D1 in the regulation of several transcription factors \[[@B14]\], as first shown for the ER \[[@B15],[@B16]\]. Cyclin D1 overexpression is common in CRC, but the findings regarding its prognostic value are conflicting \[[@B17]-[@B29]\]. However, the largest study to date, comprising an analysis of 602 tumors from two independent, prospective cohort studies, found an association between cyclin D1 overexpression and a prolonged survival from colon cancer \[[@B29]\].

Cyclin D1 is activated by WNT/β-catenin signaling after mutation of the adenomatous polyposis coli gene (*APC*), an important event in the initiation of colorectal neoplasia \[[@B30],[@B31]\]. WNT/β-catenin signaling is modulated by estrogens in breast cancer \[[@B32]\] and neuronal cells \[[@B33]\], and endogenous estrogens have been found to protect against APC-associated tumor formation in mice, associated with an increase in ERβ and a decrease in ERα expression in the target tissue \[[@B34]\]. Moreover, whereas both ERα and ERβ deficiency have been associated with enhanced intestinal neoplasia in mice carrying *APC*mutations, only ERα deficiency was associated with activation of WNT/β-catenin signaling \[[@B35]\], and functional studies in CRC cells have demonstrated antiproliferative and antitumorigenic effects of ERβ overexpression, despite a functional link to increased cyclin D1 levels \[[@B36]\]. A potential involvement of cyclin D1 in the pathway to CRC, involving mismatch repair, has also been suggested \[[@B37]\], and in the study by Ogino *et al*., an interaction between cyclin D1 expression and microsatellite instability (MSI) status was reported; the presence of either cyclin D1 or high MSI, or both, was associated with a better prognosis \[[@B29]\].

Because cyclin D1 expression is modulated by hormonal activity, we hypothesized that its expression and prognostic effects might differ according to gender in CRC. The aim of this study was therefore to analyze the immunohistochemical expression and prognostic significance of cyclin D1, with particular reference to sex-related differences, in 626 incident cases of CRC in the prospective, population-based cohort Malmö Diet and Cancer Study (MDCS) \[[@B38]\], from which 557 tumors had been assembled in tissue microarrays (TMAs).

Methods
=======

Ethics approval for the MDCS (reference 51/90) and the present study (reference 530/2008), were obtained from the Ethics Committee at Lund University.

The Malmö Diet and Cancer Study
-------------------------------

The MDCS is a population-based, prospective cohort study with the main aim to examine whether a western diet rich in fat and low in fruit and vegetables increases the risk of certain forms of cancer \[[@B38]\]. Between 1991 and 1996, a total of 28,098 participants (11,063 men (39.4%) and 17.035 women (60.6%)) aged between 44 and 74 years where enrolled (from a background population of 74,138). Follow-up is performed annually by record linkage to national registries for cancer and cause of death.

Incident colorectal cancer until 31 December 2008
-------------------------------------------------

Until the end of follow-up on 31 December 2008, 626 incident cases of CRC had been registered in the study population. Cases were identified from the Swedish Cancer Registry until 31 Dec 2007 and from the Southern Swedish Regional Tumour Registry for the period 1 January to 31 December 2008. All tumors for which slides or paraffin wax tissue blocks were available were histopathologically re-evaluated using hematoxylin and eosin staining. Histopathological, clinical and treatment data were obtained from the clinical- and/or pathology records. Information on vital status and cause of death was obtained from the Swedish Cause of Death Registry until 31 Dec 2009. Follow-up started at date of diagnosis and ended at death, emigration or 31 December 2009, whichever came first.

Tissue microarray construction
------------------------------

In total, 557 (89.0%) tumors were available and suitable for TMA construction (see Additional File [1](#S1){ref-type="supplementary-material"}). Areas representative of cancer were marked on hematoxylin and eosin-stained slides, and TMAs were constructed as previously described \[[@B39]\]. In brief, two 1.0 mm cores were taken from each tumor and mounted in a new recipient block using a semi-automated arraying device (TMArrayer; Pathology Devices, Westminster, MD, USA).

Immunohistochemistry and evaluation of cyclin D1 staining
---------------------------------------------------------

For immunohistochemical analysis, 4 μm TMA sections were automatically pretreated using a pretreatment module (PT-Link; Dako, Glostrup, Denmark) and then stained (Autostainer Plus; Dako) with the monoclonal anti-cyclin D1 antibody DSC-6 (Dako), diluted 1:50. This antibody has been validated and used for staining of formalin-fixed paraffin wax-embedded tissue in several previous studies \[[@B40]-[@B42]\].

We recorded the intensity of nuclear cyclin D1 expression (no, weak, moderate or strong), and the proportion of positive tumor cells (0 = 0 to 1%, 1 = 2 to 25%, 2 = 26 to 50%, 3 = 51 to 75%) and 4 = \> 75%). For further statistical analyses, cyclin D1 expression was dichotomized into negative (no expression and positive (any expression; fraction and intensity). The staining was evaluated by two independent observers (SW and KJ), who were blinded to the clinical and outcome data. Any scoring differences were discussed in order to reach consensus.

Statistical analysis
--------------------

The χ^2^and Spearman\'s ρ tests were used for comparison of cyclin D1 expression and relevant clinicopathological characteristics. Kaplan-Meier analysis and log-rank test were used to illustrate differences in cancer-specific survival (CSS) according to cyclin D1 expression. Cox regression proportional hazards models were used for estimation of hazard ratio (HR) for death from CRC according to cyclin D1 expression in both univariate and multivariate analyses, adjusted for age, gender, TNM stage, differentiation grade and vascular invasion. The interaction between cyclin D1 expression and gender was explored by a Cox model including the interaction variable. All survival analyses were repeated with overall mortality as endpoint and all tests were two-sided. *P*\< 0.05 was considered significant. All statistical analyses were performed using SPSS software (version 18; SPSS Inc, Chicago, IL, USA).

Results
=======

Distribution of clinicopathological characteristics and cyclin D1 expression in the full cohort and in subgroups according to gender
------------------------------------------------------------------------------------------------------------------------------------

There was no significant difference in the distribution of clinicopathological characteristics or treatment in subgroups according to gender (Table [1](#T1){ref-type="table"}). The distribution of clinicopathological characteristics did not differ between the full cohort (n = 626) and the evaluated cohort (n = 527) (data not shown). There was no sex-related difference in survival for patients with metastatic CRC (Table [1](#T1){ref-type="table"}). After antibody optimization and staining, cyclin D1 expression could be evaluated in 527of 557 tumors (94.6%) represented in the TMA. The tissue cores that could not be evaluated either had been lost during immunohistochemical processing or did not contain invasive cancer.

###### 

Patient and tumor characteristics in the evaluated cohort and in subgroups according to gender

                                   All, n = 527   Female, n = 276 (52.4%)   Male, n = 251 (47.6%)   *P*value^a^
  -------------------------------- -------------- ------------------------- ----------------------- -------------
  Age                                                                                               
   Mean                            70.5           70.6                      70.4                    0.399
   Median                          71.4           72                        70.9                    
   Range                           49.8 to 85.6   49.8 to 85.2              51.8 to 85.6            
  Location                                                                                          
   Colon                           323 (61.3)     176 (63.8)                147 (58.6)              0.256
   Rectum                          190 (36.1)     92 (33.3)                 98 (39.0)               
   Multiple                        12 (2.3)       7 (2.5)                   5 (2.0)                 
   Unknown                         2 (0.4)        1 (0.4)                   1 (0.4)                 
  T Stage                                                                                           
   1                               46 (8.7)       31 (11.2)                 15 (6.0)                0.506
   2                               63 (12.0)      30 (10.9)                 33 (13.1)               
   3                               319 (60.5)     159 (57.6)                160 (63.7)              
   4                               78 (14.8)      42 (15.2)                 36 (14.3)               
  Unknown                          21 (4.0)       39 (12.0)                 38 (12.7)               
  N stage                                                                                           
   0                               278 (52.8)     144 (52.2)                134 (53.4)              0.494
   1                               118 (22.4)     68 (24.6)                 50 (19.9)               
   2                               85 (16.1)      36 (13.0)                 49 (19.5)               
   Unknown                         46 (8.7)       28 (10.1)                 18 (7.2)                
  M Stage                                                                                           
   0                               429 (81.4)     226 (81.9)                203 (80.9)              0.513
   1                               90 (17.1)      44 (15.9)                 46 (18.3)               
   Unknown                         8 (1.5)        6 (2.2)                   2 (0.8)                 
  Differentiation grade                                                                             
   High                            34 (6.5)       19 (6.9)                  15 (6.0)                0.438
   Intermediate                    367 (69.6)     185 (67.0)                182 (72.5)              
   Low                             118 (22.4)     67 (24.3)                 51 (20.3)               
   Unknown                         8 (1.5)        5 (1.8)                   3 (1.2)                 
  Vascular invasion                                                                                 
   No                              150 (28.5)     81 (29.3)                 69 (27.5)               0.635
   Yes                             156 (29.6)     80 (29.0)                 76 (30.3)               
   Unknown                         222 (41.9)     115 (41.7)                106 (42.2)              
  Surgery                                                                                           
   Acute                           46 (8.7)       26 (9.4)                  20 (8.0)                0.502
   Elective                        454 (86.1)     233 (84.4)                221 (88.0)              
   Unknown                         27 (5.1)       17 (6.2)                  10 (4.0)                
  Neodjuvant treatment                                                                              
   None                            414 (78.6)     216 (83.4)                198 (82.2)              0.291
   Short RT                        25 (4.7)       10 (3.9)                  15 (6.2)                
   Long RT                         19 (3.6)       8 (3.1)                   11 (4.6)                
   Chemotherapy + RT               2 (0.4)        2 (0.8)                   0 (0.0)                 
   Chemotherapy                    2 (0.4)        1 (0.4)                   1 (0.4)                 
   Unknown                         65 (12.3)      39 (14.1)                 16 (10.4)               
  Adjuvant treatment                                                                                
   No                              294 (55.8)     149 (54.0.8)              145 (57.8)              0.584
   FLV/Xeloda                      51 (9.7)       25 (9.1)                  26 (10.4)               
   FLOX/XELOX                      19 (3.6)       11 (4.0)                  8 (3.2)                 
   Other                           5 (0.9)        4 (1.4)                   1 (0.4)                 
   Curative; M1\*                  14 (2.7)       6 (2.2)                   8 (3.2)                 
   Palliative                      80 (15.2)      39 (14.1)                 41 (16.3)               
   Unknown                         64 (12.1)      42 (15.2)                 22 (8.8)                
  Follow-up (years)                                                                                 
   Mean                            4.7            4,9                       4.5                     0.399
   Median                          3.5            3.4                       3.4                     
   Range                           0.0 to 17.7    0.0 to 17.7               0.0 to 16.6             
  Vital status                                                                                      
   Alive                           306 (58.1)     169 (61.2)                137 (54.6)              0.113
   Dead                            221 (41.9)     107 (38.8)                114 (45.4)              
   Dead from CRC                   182 (34.5)     90 (32.6)                 92 (36.7)               0.313
  Follow-up (years); M1 patients                                                                    
   Mean                            1.5            1.3                       1.6                     0.129
   Median                          1.1            0.8                       1.2                     
   Range                           0.0 to 6.1     0.0 to 5.5                0.0 to 6.1              
  Vital status; M1 patients                                                                         
   Alive                           12 (13.3)      7 (15.9)                  5 (10.9)                0.484
   Dead                            78 (86.7)      37 (84.1)                 41 (89.1)               
   Dead from CRC                   78 (86.7)      37 (84.1)                 41 (89.1)               0.484
  Cyclin D1 fraction                                                                                
   0 to 1                          105 (19.9)     50 (18.1)                 55 (21.9)               0.217
   02 to 25                        195 (37.0)     100 (36.2)                95 (37.8)               
   26 to 50                        86 (16.3)      48 (17.4)                 38 (15.1)               
   51 to 75                        112 (21.3)     64 (23.2)                 48 (19.1)               
   \> 75                           29 (5.5)       14 (5.1)                  15 (6.0)                
  Cyclin D1 intensity                                                                               
   Negative                        105 (19.9)     50 (18.1)                 55 (21.9)               0.018
   Weak                            181 (34.3)     85 (30.8)                 96 (38.2)               
   Moderate                        176 (33.4)     102 (37.0)                74 (29.5)               
   Strong                          65 (12.3)      39 (14.1)                 26 (10.4)               

**^a^**The *P*values refer to comparisons of male and female tumors, using the Mann-Whitney*U*-test for comparison of medians and the χ^2^test for X × 2 tables. P-values for vital status refer to overall and cause-specific death, respectively. The categories marked as \'not done\' and \'unknown\' were not included in the statistical analysis.

Abbreviations: FLOX = 5-fluorouracil, leucovorin and oxaliplatin, FLV = 5-fluorouracil and leucovorin, RT = radiotherapy, XELOX = Xeloda (capecitabine) and oxaliplatin.

Representative immunohistochemistry images are shown in Figure [1](#F1){ref-type="fig"}. Cyclin D1 expression was only rarely seen in inflammatory cells and stromal cells. Of the 527 tumors evaluated, 105 (16.8%) were negative for cyclin D1; in the remaining tumors, cyclin D1 was expressed in various fractions and intensities (Table [1](#T1){ref-type="table"}). The intensity but not the fraction of cyclin D1 was significantly lower in male compared with female CRC (*P*= 0.018).

![**Immunohistochemical images of cyclin D1 staining in colorectal cancer**. (A,B) Negative staining, (C,D) various fractions of weak to moderate staining, and (D-F) strong cyclin D1 staining. Original magnification × 20.](2042-6410-2-10-1){#F1}

Association between Cyclin D1 expression and clinicopathological characteristics in the full cohort and the subgroups according to gender
-----------------------------------------------------------------------------------------------------------------------------------------

Next, we examined the relationship between cyclin D1 expression (fraction and intensity) and established clinicopathological parameters in all patients, both female and male (Table [2](#T2){ref-type="table"}). We found a significant inverse correlation between cyclin D1 fraction (but not intensity) and the N (*R*= -0.014, *P*= 0.012) and M (*R*= -0.091, *P*= 0.039) stages in the full cohort. This association was not evident in women, but in men, both the fraction and intensity of cyclin D1 staining were inversely correlated with N stage (R = -0.134, *P*= 0.041 for fraction and R = -0.153, *P*= 0.020 for intensity) and M stage (R = -0.143, *P*= 0.024 for fraction and R = -0.161, *P*= 0.011 for intensity). In the full cohort, but not in subgroups according to gender, there was a positive association between cyclin D1 fraction (but not intensity) and age (R = 0.101, *P*= 0.020), and an inverse association with T stage (R = -0.105, *P*= 0.018). Cyclin D1 fraction, but not intensity, was also inversely associated with vascular invasion in the full cohort (R = -0.121, *P*= 0.034) and in women (R = -0.175, *P*= 0.026), but not in men.

###### 

Associations between cyclin D1 expression and clinicopathological characteristics in all patients, females and males

                          All       Female   Male                         
  ----------------------- --------- -------- --------- -------- --------- ---------
  Age                                                                     
   *R*                    0.101     0.064    0.111     0.090    0.083     0.022
   *P*value               0.020\*   0.142    0.065     0.134    0.189     0.73
   n                      527       527      276       277      251       251
  T stage                                                                 
   *R*                    -0.105    -0-086   -0.105    -0.072   -0.104    -0.098
   *P*value               0.018\*   0.053    0.09      0.245    0.107     0.128
   n                      506       506      262       262      244       244
  N stage                                                                 
   *R*                    -0.114    -0.079   -0.094    -0.003   -0.134    -0.153
   *P*value               0.012\*   0.085    0.140     0.962    0.041\*   0.020\*
   n                      481       481      248       248      233       233
  M stage                                                                 
   *R*                    -0.091    -0.064   -0.039    0.030    -0.143    -0.161
   *P*value               0.039\*   0.147    0.520     0.628    0.024\*   0.011\*
   n                      519       520      270       270      249       249
  Differentiation grade                                                   
   *R*                    -0.051    0.044    -0.095    0.007    -0.004    0.076
   *P*value               0.243     0.310    0.116     0.908    0.948     0.232
   n                      527       527      276       276      251       251
  Vascular invasion                                                       
   *R*                    -0.121    -0.068   -0.175    -0.109   -0.065    -0.018
   *P*value               0.034\*   0.233    0.026\*   0.167    0.435     0.830
   n                      306       306      161       1611     145       145

Abbreviations: n = number (sample size); R = Spearman\'s correlation coefficient.

\*Significant at the 0.05 level; \*\*Significant at the 0.01 level.

Association between cyclin D1 expression and survival
-----------------------------------------------------

The prognostic value of established clinicopathological parameters did not differ between women and men (see Additional File [2](#S2){ref-type="supplementary-material"}). Kaplan-Meier analysis showed that cyclin D1 expression, both fraction and intensity, was associated with a stepwise improvement in CSS in all patients (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). However, subgroup analysis according to gender showed that this association was not significant in female patients (Figure [2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}) but was highly significant, and even accentuated, in male patients (Figure [2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). These associations were confirmed in univariate Cox regression analysis (Table [3](#T3){ref-type="table"}) but did not remain significant in multivariate analysis adjusted for age, gender, TNM, differentiation grade and vascular invasion (Table [3](#T3){ref-type="table"}). The results were not significantly altered when vascular invasion or cases with missing information on vascular invasion were excluded from the analysis (data not shown).

![**Association between cyclin D1 expression and survival in all patients and in subgroups according to gender**. Kaplan-Meier analysis of colorectal cancer-specific survival according to cyclin D1 fraction and intensity, respectively, in (A,B) all patients, (C,D) female patients and (E,F) male patients.](2042-6410-2-10-2){#F2}

###### 

Cox univarate and multivariate proportional hazards analysis of colorectal cancer-specific survival in all patients

  Cyclin D1 expression   Univariate            Multivariate                                                                  
  ---------------------- --------------------- -------------- ---------- ------- --------------------- ----------- --------- -------
  All patients                                                                                                               
   Low                   1.00                  105 (48)                          1.00                  99 (45)               
   High                  0.69 (0.49 to 0.96)   422 (134)      0.026      0.024   1.08 (0.75 to 1.58)   377 (113)   0.671     0.429
  Female                                                                                                                     
   Low                                         1.00           50 (17)                                  1.00        47 (16)   
   High                  1.05 (0.62 to 1.78)   226 (73)       0.864              1.35 (0.75 to 2.41)   199 (60)    0.313     
  Male                                                                                                                       
   Low                                         1.00           55 (31)                                  1.00        52 (29)   
   High                  0.48 (0.31 to 0.74)   196 (61)       \< 0.001           0.90 (0.53 to 1.53)   178 (53)    0.712     

Abbreviations: HR = hazard ratio.

^a^*P*value from multivariate analysis adjusted for T stage (1 to 2 versus 3 to 4), N stage (0 versus 1 to 2), M stage (0 versus1), age (≤ or ≥ 75 years), differentiation grade (high to intermediate versus low) and vascular invasion (absent, present, missing). Sex was included in the multivariate analysis for all patients.

^b^*P*value for term of interaction by Cox multivariate analysis including gender, the binary covariate cyclin D1 expression and a term of interaction.

^c^*P*value for term of interaction adjusted for T stage (1 to 2 versus 3 to 4), N stage (0 versus 1 to 2), M stage (0 versus1), age (≤ or ≥ 75 years), differentiation grade (high to intermediate versus low) and vascular invasion (absent, present, missing).

Cox interaction analysis confirmed a significant interaction between cyclin D1 status and gender (p~interaction~= 0.024), which was not retained when adjusted for conventional prognostic markers (Table [3](#T3){ref-type="table"}). Next, we constructed a combined variable of gender and cyclin D1 status, which showed that, in the full cohort, men with cyclin D1-negative tumors had a significantly impaired CSS compared with men with cyclin D1-positive tumors and compared with all women, irrespective of cyclin D1 status (Figure [3A](#F3){ref-type="fig"}). These associations were not evident in subgroup analysis of patients with stage I-II disease (Figure [3B](#F3){ref-type="fig"}), but remained significant for patients with stage III-V disease (Figure [3C](#F3){ref-type="fig"}). In patients with stage III (T1-4, N1-2, M0) disease (n = 126), of whom 65 (51.6%) had received adjuvant chemotherapy and 61 (48.4%) had not, the prognostic value of cyclin D1 was not altered by adjuvant chemotherapy, either in all patients or in subgroup analysis according to gender (data not shown).

![**Kaplan-Meier estimates of colorectal cancer-specific survival according to combinations of gender and positive versus negative cyclin D1 expression**. Colorectal cancer-specific survival in (A) all patients, (B) patients with stage I-II disease and (C) patients with stage III-IV disease. Log-rank *P*values correspond to pairwise comparisons of cyclin D1-negative tumors in male patients with the other strata, respectively.](2042-6410-2-10-3){#F3}

The sex-related effect on survival of cyclin D1 expression did not differ between cancers of the colon and rectum (data not shown).

For all analyses, similar associations were seen using overall survival, that is, death from any cause, as endpoint (data not shown).

Discussion
==========

In this study, we found that cyclin D1 expression was associated with a more favorable outcome from CRC in a large, population-based cohort study, confirming previous findings \[[@B29]\]. However, subgroup analysis according to gender revealed that the prognostic value of cyclin D1 was only evident in male but not female CRC patients, a finding that has, to our knowledge, not been reported previously. It will be of interest for future studies to investigate the molecular basis for this contrasting prognostic significance of cyclin D1 expression in women and men, with particular reference to the influence of sex-hormone levels, anthropometric factors, and genetic and epigenetic modification of steroid receptors.

Although the distribution of conventional clinicopathological and prognostic factors did not differ between female and male CRC patients in this study, the proportion of tumors with strong cyclin D1 intensity was significantly lower in the group of tumors from male patients. This association is interesting, given the protective effect of estrogen against CRC and the important role of cyclin D1 as a mediator of estrogen signaling. Notably, the majority of the female cohort examined in this study was post-menopausal, either having low/no circulating estrogens or taking HRT.

Until further knowledge about the role of cyclin D1 in CRC has been gained, we believe that evaluation of the fraction and intensity of cyclin D1 as separate categories makes sense, not least in light of previous studies in breast cancer, for which the intensity, but not fraction, of cyclin D1 expression was found to influence survival and response to antihormonal therapy \[[@B40],[@B43]\]. However, in our study, there was a similar effect of cyclin D1 on survival for both fraction and intensity, with a stepwise improvement from negative to high expression.

The association between cyclin D1 expression and clinicopathological parameters differed somewhat according to gender, with a significant inverse relationship between cyclin D1 expression and N and M stages in male but not female CRC, indicating that lack of cyclin D1 is associated with a more aggressive phenotype in male patients. However, this interpretation is somewhat dampened by the inverse association we observed between cyclin D1 expression and vascular invasion, another adverse prognostic factor, in female but not male CRC.

In contrast to the findings in the study by Ogino *et al*. \[[@B29]\], cyclin D1 expression did not remain an independent prognostic factor in multivariate analysis in our study, either in the full cohort or in the male group. The association between cyclin D1 expression and more favorable clinicopathological features might in part explain the lack of an independent prognostic value for cyclin D1 in male CRC, although the sex-related prognostic effect of cyclin D1 was evident in patients with stage III-IV disease but not in patients with stage I-II disease. Owing to the relatively small subgroups, these findings should be interpreted with caution, but it is noteworthy that a similar association was found by Ogino *et al*. \[[@B29]\]. The reason for this remains unclear, but it could be speculated that, although they are in a disseminated state, cyclin D1-expressing tumors are still less aggressive than tumors lacking cyclin D1 expression. This assumption is supported by previous studies in breast cancer, which showed an association between low cyclin D1 levels and a more invasive tumor phenotype \[[@B42]\]. Another explanation for the more evident beneficial prognostic effect of cyclin D1 in metastatic disease could be that cyclin D1 expression predicts response to adjuvant chemotherapy. However, we could not find such an effect when the prognostic influence of cyclin D1 expression was analyzed in the subgroup of patients with stage III disease, of whom a relatively large proportion had not received adjuvant chemotherapy.

Because the MDCS is a population-based cohort study, a potential selection bias compared with the general population must be taken into consideration \[[@B38]\]. The denoted frequency of acute surgery was 8.7% (8.3% in the full cohort of 626 cases), which is lower than the usually reported frequency of approximately 25% \[[@B44],[@B45]\]. This is noteworthy as it could reflect a higher awareness of CRC among study participants. However, information on surgery was missing for 5.1% of the patients (8.6% in the full cohort), and lower frequencies have been reported in other studies \[[@B46]\]. Furthermore, the distribution of clinical stages at diagnosis in our study is in line with that expected, with no favoring of less advanced stages.

In this study, we used CRC-specific survival as the primary endpoint. Notably, all associations between cyclin D1 expression and survival were similar when overall survival was used as the endpoint, and because the number of events for cancer-specific and overall survival was identical for patients with metastatic disease, with a median survival of approximately 10.5 months (range 0 to 72), the use of CSS should be a reasonable surrogate for cancer-specific outcome. In future studies, the effect of cyclin D1 expression on recurrence-free survival should also be assessed, preferably in cohorts in which this information has been recorded prospectively.

Conclusions
===========

The results from this large cohort study show that tumor-specific cyclin D1 expression is strongly associated with a prolonged survival from CRC in men but not women. These findings not only suggest an important role for cyclin D1 in colorectal carcinogenesis and progression, but also add support to the accumulating evidence that sex hormones are relevant to the development of CRC, and that prognostic and treatment-predictive molecular biomarkers should be evaluated differently in women and men.
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